Qiagen N.V.
QGEN
Positions held
Your positionsQGEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Qiagen operates in the growing diagnostics and research industry, which is expected to expand due to increasing demand for personalized medicine and advanced diagnostic solutions.
- In Q2 2026, Qiagen reported a revenue increase of 9% compared to the previous quarter, reaching $535 million.
- The company's operating margin improved to 26.3% in Q2 2026, up from 23.7% in Q1 2026.
- Despite positive trends, Qiagen's revenue growth is relatively modest at 0.3%, indicating potential challenges in market competitiveness.
- The trailing P/E ratio stands at 23.17, suggesting the stock may be overvalued compared to its earnings growth rate of 7.9%.
- The debt-to-equity ratio of 49.25 raises concerns about financial leverage and potential risks in economic downturns.
Fundamentals
| Market cap | $9.20B | Enterprise value | $10.06B | Trailing P/E | 22.60 | Forward P/E | 17.04 |
| PEG | 1.20 | Price / book | 2.74 | Beta | 0.61 | Dividend yield | 0.79% |
| Revenue growth | 0.3% | Earnings growth | 7.9% | Gross margin | 66.4% | Operating margin | 26.3% |
| Profit margin | 19.5% | ROE | 11.9% | ROA | 5.9% | Debt / equity | 0.49 |
| Current ratio | 2.85 | Free cash flow | $372.86M | Analyst recommendation | buy | Mean target | $47.47 |
| 52w high | $57.82 | 52w low | $32.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $535M | $492M | $540M | $533M | $534M | — |
| Op margin | 26.3% | 23.7% | 22.6% | 25.8% | 25.5% | — |
| Net income | $103M | $68.0M | $108M | $130M | $96.3M | — |
| Gross margin | 63.6% | 62.9% | 60.2% | 62.2% | 62.7% | — |
| Gross profit | $340M | $310M | $325M | $331M | $334M | — |
| Operating income | $141M | $117M | $122M | $137M | $136M | — |
- Revenue +9% vs prior quarter ($535M vs $492M).
- Gross margin 63.6% (was 62.9% prior quarter).
- Operating margin expanded to 26.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.1B | $2.0B | $2.0B | $2.1B | — |
| Op margin | 24.9% | 10.1% | 22.7% | 26.9% | — |
| Net income | $425M | $83.6M | $341M | $423M | — |
| Gross margin | 62.2% | 48.9% | 62.8% | 64.7% | — |
| Gross profit | $1.3B | $967M | $1.2B | $1.4B | — |
| Operating income | $520M | $200M | $445M | $576M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
2026-10-06 · Barclays Upgrades QIAGEN to Overweight From Equalweight
2026-10-02 · QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
2026-09-29 · Qiagen (QGEN), What Is Behind The Fresh Attention Now?
2026-09-29 · What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For Shareholders
2026-09-28 · QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
2026-09-24 · QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
2026-09-24 · QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
2026-09-24 · Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
2026-09-18 · QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
Price (daily)
Full chart · RSI · MACD · patterns